Research Article

A Meta-Analysis of Arsenic Trioxide Combined with Transcatheter Arterial Chemoembolization for Treatment of Primary Hepatic Carcinoma

Table 1

The basic facts of inclusion in literature.

Included studiesSex (man/woman)
(E/C)
Age
(E/C)

(E/C)
Experiment group interventionControl group interventionOutcomesChild-Pugh
A/B/C ()

Qi et al., 2003 [13]28/6
24/6
32~68
36~72
34/30As2O3 (20 mg/d, qd) + TACETACE (5-Fu 1 g + MMC 10 mg + Epi-ADM 60 mg + iodised oil 10–30 mL, iv, 35 days)Clinical effect,
AFP, survival
E: 28/4/2
C: 22/4/4

Cui et al., 2006 [7]21/5
25/4
39~65
37~67
26/29As2O3 (20 mg/d, qd) + TACETACE (MMC 6 mg/m2 + Epi-ADM 40 mg/m2 + iodised oil 10–30 mL, iv, 35 days)Clinical effect,
AFP, survival
E: NR
C: NR

Zhuang et al., 2006 [10]44/18
36/20
26~76
24~79
62/56As2O3 (20 mg/d, qd) + TACETACE (cisplatin 50 mg + MMC 10 mg + Epi-ADM 50 mg + iodised oil 10–30 mL, iv, 60 days)Clinical effect,
AFP, survival
E: 28/32/2
C: 25/28/3

Xie et al., 2007 [14]25/8
23/9
21~70
21~70
33/32As2O3 (20 mg/d, qd) + TACETACE (HCP 20 mg + ADM 50 mg + cisplatin 60 mg + iodised oil 5–20 mL, iv, 42 days)Clinical effect,
AFP, survival,
quality of life
E: NR
C: NR

Zhou et al., 2007 [15]35/6
40/5
21~75
23~74
41/45As2O3 (20 mg/d, qd) + TACETACE (5-FU 750 mg + CAP 300 mg + THP 60 mg + iodised oil 2–5 mL, iv, 28 days)Clinical effect,
AFP
E: 35/6/0
C: 37/8/0

Wang, 2012 [5]26/4
25/5
44~64
47~67
30/30As2O3 (20 mg/d, qd) + TACETACE (CAP 300 mg + MMC 10 mg + iodised oil 5–20 mL, iv, 28 days)Clinical effect,
AFP, quality of life
E: NR
C: NR

Kui et al., 2010 [11]UnclearUnclear16/15As2O3 (20 mg/d, qd) + TACETACE (5-Fu 750 mg/m2 + cisplatin 60 mg + THP 20 mg/m2, iv, 14 days)Clinical effect,
survival
E: NR
C: NR

Huang, 2011 [4]13/2
11/4
48~68
45~71
15/15As2O3 (10 mg/d, qd) + TACETACE (THP 20–40 mg + 5-Fu 500–750 mg + iodised oil, iv, 28 days)Clinical effect,
survival
E: NR
C: NR

Zhang et al., 2011 [12]24/6
25/5
28~72
31~68
30/30As2O3 (20 mg/d, qd) + TACETACE (CAP 300 mg + MMC 10 mg + iodised oil 5–20 mL, iv, 42 days)Clinical effect,
quality of life
E: NR
C: NR

Meng et al., 2012 [8]22/8
19/11
36~77
23~78
30/30As2O3 (10 mg/d, qd) + TACETACE (ADM 20–30 mg + capobenic 100–300 mg + iodised oil 6–20 mL, iv, 56 days)Clinical effect,
quality of life
E: NR
C: NR

Xing, 2012 [9]18/5
23/2
44~66
46~64
23/25As2O3 (20 mg/d, qd) + TACETACE (Epi-ADM 40 mg + saline 2 mL + iodised oil, iv, 28 days)Clinical effect,
survival
E: NR
C: NR

Hu et al., 2014 [16]21/7
17/8
31~80
28~70
28/25As2O3 (10–20 mg/d, qd) + TACETACE (oxaliplatin 150 mg + 5-FU 1.5 g + Epi-ADM 50 mg + iodised oil 10–20 mL, iv, above 28 days)Clinical effect,
AFP, survival,
quality of life
E: NR
C: NR

Qian, 2014 [17]32/8
35/5
33~81
31~68
40/40As2O3 (20 mg/d, qd) + TACETACE (lobaplatin 20 mg + Epi-ADM 40 mg, iv, 28 days)Clinical effect,
AFP, quality of life
E: NR
C: NR

Wan et al., 2014 [18]16/9
18/7
44~66
42~64
25/25As2O3 (10 mg/d, qd) + TACETACE (Epi-ADM 40 mg/m2 + 5-Fu 1000 mg/m2 + cis-platinum 50 mg/m2 + iodised oil 5–20 mL, iv, above 28 days)Clinical effect,
AFP, quality of life
E: NR
C: NR

Xiang, 2014 [19]22/5
25/3
49~71
47~69
27/28 As2O3 (15 mg/d, qd) + TACETACE (THP 20 mg + MMC 10 mg + iodised oil, iv, above 28 days)Clinical effect,
AFP, survival,
quality of life
E: 24/3
C: 24/4

Meng et al., 2015 [20]27/3
26/4
36~76
36~72
30/30As2O3 (10 mg/d, qd) + TACETACE (oxaliplatin 100 mg + ADM 20–30 mg + iodised oil 3–15 mL, iv, 14 days)Clinical effect,
quality of life
E: NR
C: NR

Yang and Li, 2015 [21]21/19
22/18
57~62
59~64
40/40As2O3 (10 mg/d, qd) + TACETACE (ADM 20–40 mg/m2 + cis-platinum 20–40 mg/m2 + iodised oil, iv, 28 days)Clinical effect,
AFP, survival
E: NR
C: NR

E, experimental group for As2O3 with TACE in treating PHC; C, control group for TACE in treating PHC; NR, not reported; MMC, mitomycin; ADM, adriamycin; Epi-ADM, Epirubicin Hydrochloride; HCPT, hydroxy camptothecin; 5-FU, 5-fluorouracil; CAP, carboplatin; THP, pirarubicin.